Latest Breaking News On - Akseli hemminki - Page 1 : comparemela.com

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024

Results Reveal Mechanism of Action and Correlative Analyses DataHELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024. TILT-123 in combination with MS

Finland's TILT Biotherapeutics gets $2M grant from US Department of Defense for ovarian cancer immunotherapy research

TILT Biotherapeutics awarded $2 million grant for ovarian cancer research

TILT Biotherapeutics, a clinical-stage biotech company developing cancer immunotherapies, has received a $2 million grant from the U.S. Department of Defense (DOD) for a three-year project to treat ovarian cancer using its TILT-123 asset.

TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research